Nivolumab & Bladder cancer

FDA status:

In the context of Nivolumab & Bladder cancer, the FDA initially approved nivolumab for adults with locally advanced or metastatic urothelial carcinoma that had progressed during or after platinum-containing chemotherapy. Later, the FDA approved adjuvant nivolumab for patients with high-risk muscle-invasive urothelial carcinoma following radical surgery, as demonstrated in the CheckMate 274 trial. This approval marked nivolumab as the first checkpoint inhibitor sanctioned for use in the adjuvant setting for urothelial cancer (1, 2, 3, 4, 5, 6)

EMA status:

In [Europe](brain:…